CA1045548A - Tissue absorbable polymer sponge - Google Patents
Tissue absorbable polymer spongeInfo
- Publication number
- CA1045548A CA1045548A CA219,627A CA219627A CA1045548A CA 1045548 A CA1045548 A CA 1045548A CA 219627 A CA219627 A CA 219627A CA 1045548 A CA1045548 A CA 1045548A
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- sponge
- poly
- acid
- polyglycolic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002993 sponge (artificial) Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 9
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical group FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims abstract description 8
- VAIZVCMDJPBJCM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-one;trihydrate Chemical compound O.O.O.FC(F)(F)C(=O)C(F)(F)F.FC(F)(F)C(=O)C(F)(F)F VAIZVCMDJPBJCM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002874 hemostatic agent Substances 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000007710 freezing Methods 0.000 claims abstract description 3
- 230000008014 freezing Effects 0.000 claims abstract description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 24
- 239000004633 polyglycolic acid Substances 0.000 claims description 23
- 229950008885 polyglycolic acid Drugs 0.000 claims description 23
- -1 poly(N-acetyl-D-glucosamine) Polymers 0.000 claims description 17
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 230000002439 hemostatic effect Effects 0.000 claims description 6
- 229920001519 homopolymer Polymers 0.000 claims description 6
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000000356 contaminant Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000001356 surgical procedure Methods 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 2
- 239000010839 body fluid Substances 0.000 abstract description 2
- 239000006260 foam Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 14
- 239000000203 mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 4
- 208000035871 PIK3CA-related overgrowth syndrome Diseases 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000000859 sublimation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- MSWVMWGCNZQPIA-UHFFFAOYSA-N 1-fluoropropan-2-one Chemical compound CC(=O)CF MSWVMWGCNZQPIA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
ABSTRACT OF THE INVENTION
A conformable tissue absorbable surgical sponge is formed by dissolving a tissue absorbable polymer is hexa-fluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering, freezing and subliming off the solvent to give a tissue conformable flexible sponge which rapidly absorbs blood and other body fluids. The sponge may be used to absorb blood or other liquids during a surgical procedure or may be used as a hemostat and allowed to remain in a closed wound with the polymer being absorbed by living tissue.
A conformable tissue absorbable surgical sponge is formed by dissolving a tissue absorbable polymer is hexa-fluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering, freezing and subliming off the solvent to give a tissue conformable flexible sponge which rapidly absorbs blood and other body fluids. The sponge may be used to absorb blood or other liquids during a surgical procedure or may be used as a hemostat and allowed to remain in a closed wound with the polymer being absorbed by living tissue.
Description
25,013 ~o45s48 BACKGROUND OF ~HE I~ENTION
Surgical sponges find many uses in which an ab~
sorbent sponge is desirable to soak up blood, serum, or other body fluids, which sponges are removed and discarded. Cotton gauze sponges are used in many instances. When used inter-nally, there is a problem of part of the sponge coming off -and leaving threads or larger portions of the sponge in the wound. Concern over leaving a sponge in a patient complicates operating room practice and involves extremely rigorous count-ing procedures to insure that no sponge is accidentally left in a closed wound.
In many surgical procedures reguiring a hemostat to control bleeding sutures and tieoffs can be used. In some in-stances it is highly desirable that additional methods of controlling bleeding be made available. More or less success-ful efforts have been made to secure conformable hemostats which can be used to control bleeding and then left in the wound. The problem is well recognized and more acceptable - devices are in constant demand. ~
DESCRIP~ION 0~ TH~ PRIOR AR~ ~ -The use of polyglycolic acid is disclosed in a series of patents and applications to Schmitt, et al: -. .
U. S. Patent 3,297,033, Schmitt and Polistina, January 10, 1967, SURGICAL SUTURES, discloses polyhydroxy--acetic ester absorbable sutures. ~he material is also called polyglycolic acid, and is disclosed as permitting small quan- ~ -tities of comonomers to be present, such as dl-lactic acid, its optically active forms, homologs and analogs. A small - ~-quantity is recognized by the art as up to 15%, as shown by : , ~- 30 U. S. Patent 2,668,162, ~owe, ~ebruary 2, 1954, PREPARATION
0~ HIGH MO~ECU~AR WEIGH~ PO~YHYDROXY-ACETIC ES~ER. -~ ~
. ~:
. . ~, . . .
25,013 55~8 U. S. Patent 3,463,158, Schmitt and Polistina, August 26, 1969, PO~YGLYCOLIC ACID PROS~HETIC DEVICES, dis-closes surgical uses of polyglycolic acid, and incorporates definitions of some terms.
U. S. Patent 3,620,218, Schmitt and Polistina, November 16, 1971, CY~INDRICAL PROS~HE~IC DEVICES OF PO~Y-G~YCOLIC ACID, lists many uses of polygl~colic acid.
U. S. Patent 3,736,646, Schmit-t and Epstein, June 5, 1973, METHOD OF A~rlACHING SURGICA~ NEEDLES TO MUL~IFILAMEN~ -PO~YGLYCO~IC ACID ABSORBABIE SUTURES, discloses surgical elements of a copolymer containing from 15 to 8~ mol percent glycolic acid and 85 to 15 mol percent lactic acid.
U. S. Patent 3,739,773, Schmitt and Polistina, June 19, 1973, PO~YG~YCOLI~ ~CID PROS~HEr~IC DEVIC~S, claims particularly bone pins, plates, nails and screws of polygly-colic acid.
U. S. Application Serial No. 365,656, Schmitt and Polistina, May 31, 1973, SURGICA~ DRESSI~GS 0~ ABSORBABLE
POLYMERS, discloses additional subject matter on surgical dressings of polyglycolic acid. ;-~
U. S. Patent 3,739,773, supra, lis-ts a number of U~ S. patents on methods for preparing polyglycolic acid and starting materials therefor.
In U. S. Ratent 3,620,218, supra, in Column 2 are Z5 listed a number of medical uses of polyglycolic acids, in~
cluding in Column 2; line 52, knit-ted or woven fibrillar products, including velours, and mentioning specifically in -line 53, burn dressings; line 57, felt or sponge for liver hemostasis; line 63, foam as absorbable prosthesis; and in -lines 74 and 75~ burn dressings (in combination with other polymeric films).
U. S. Patent 3,737,440, Schmitt and Bailey, June 5 . . . - -3L~45S48 1973, POLYGLYCOLIC ACID IN SOLUTIONS, discloses solutions of polyglycolic acid in hexafluoroisopropyl alcohol and hexa- ~`
fluoroacetone sesquihydrate, as well as wet and dry spinning of filaments and casting of films using t:hese solutions.
U.S Patent 3,783,093, Gallacher, January 1, 1974, FIBROUS POLYETHYLENE MATERIALS, discloses a fibrillated ma-terial, mentioning poly(glycolic acid) among others~ in which one resin is mixed and fibrillated with another, and one resin leached out to give the product, a web of oriented, intercon-nected directional fiber-like strands, membranes, ribbons, branched ribbons and fibrils. These can be used as bandages and for other medical purposes. Example 15 shows 25 parts of poly(glycolic acid) and 75 parts of poly (methyl methacrylate) leached with acetone.
US Patent 2,899,362, Sieger, Valentine, and Weiden-heimer, Augu~t 11, 1959, HEMOSTATIC SPONGES AND METHOD OF PRE-PARING SAME, discloses a whipped starch-gelatin mixture which is aerated and dried to form a sponge which may be used for hemostatic purposes.
US Patent 3,653,383, Wise, April 4, 1972, ALGIN
SPONGE AND PROCESS THEREFOR, discloses algin sponges made by freeze-drying aqueous alginate dispersions or gels which can be used for burn dressings, and other surgical purposes. The product after use is water-disintegrative.
Commercially, an oxidized regenerated cellulose is available, as a gelatin foam distributed in sheet form. Both oE these are absorbable in tissues. Under some conclitions, the gelatin foam causes bile cysts. It is desirably wetted with saline at the time of use.
~ .
`
`` 3L~)~55~
The use of gauzes, felts, and knitted fabr;cs as a wound dressing is quite conventional. The use of collagenous products as a sponge or pad has been disclosed. The requirements for surgical hemostats are varied and more satisfactory hemostats than presently available are constantly in demand.
The present invention provides a method of making a hemostat comprising dissolving a ~issue-absorbable polymer seLected from polyglycolic acid, poly~N-acetyl-D-glucosamine), and poly(4-methyl, 1,4-dioxane 2,5-dione) in hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering to remove any insoluble contaminants, freezing the solution and subliming off the solvent, whereby an absorbable sponge fibrillar structure is formed ~ -from ribbons having a thickness within the range of from 1 to 5 microns which is essentially non-directional and is readily conformable to tissue surfaces.
The present invention also provides a hemostatic surgical sponge of a tissue absorbable polymer selected from polyglycolic acid, polyXN-acetyl-D-glucosamine), and poly(~-methyl,1,4-dioxana-2,5-dione) in the form of a fibrillar sheet having interconnected ribbons having a thickness within the range of from 1 to 5 microns oriented anisotropically having a network of connecting elements, and which is sufficiently flexible to be readily con-formable to a wound surface.
Such sponges may be used in procedures in which the foam sponge is to be left in the wound and absorbed by body tissues and also sees great acceptance in sponges which are used to absorb blooa, serum or other liquids with the sponge being Temoved and discarded. Because there is the ever present risk of part of the sponge falling off and being left in the wound or through inadvertence being closed in the wound, it is desirable that tissue absorbable sponges be used for general surgical use, wherever tissue may grow into the sponge.
A sponge should have high absorptive capacity, should absorb :;~ ,.' .'""~:, ~, ..
~455~
fluids, particularly blood, rapidly, should be strong enough to be readily handled in surgical procedures, and conformable enough that it fits into whatever topography and space that is available, and be soft enough so that it does not injure sensitive tissues.
The absorbability of the present sponges by the body reduces the risks from the inadvertent enclosure of portions of a hemostatic sponge in living tissue--because such portions are absorbed and removed by the tissue itself.
- 4a -: -25,013 ~ S ~8 Although freeze drying is a well-known technique~
it i5 usually drying of water from frozen compositions in which water is to be removed by sublimation; and the product is usually rather brittle and friable so that it is not readily conformable, and is easily broken.
Here the solvent, which is removed by sublimation, is hexafluoroisopropyl alcohol or hexafluoroace-tone sesqui-hydrate or a mixture of the two. The residual foam is softer and more conformable than products usually secured ``
from aqueous systems. I-t is, of course, not possible to use an aqueous system with the tissue absorbable polymer of this invention. ~he polymers are not water soluble.
Because ~he solvent is volatile, and is sublimed to remove the major portion, and the resulting cake is dried to remove the small remaining portion, the absorbable sponge `
struc-ture is more readily freed from other components than in a leach technique using a mixture of polymers in which ;~
one polymer is leached ou-t, thus requiring elimination of not only the leached polymer, but also the leaching solvent.
Because the term "freeze-drying" sometimes implies an agueous system, the term "sublimation-drying" is used in many places herei~ to accen-tuate tha-t it is an organic sol- ~`
vent system which is being subllmed so tha-t it could be ;
called solven-t-sublimation for sponge manufacture. Products prepared in an aqueous system are generally friable. Using -hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate as a solvent for polyglycolic acid, and other tissue absorbable compositions~ yields a product which is readily flexible and tissue conformable.
3 Because homopolymeric polyglycolic acid is currently being used in sutures, has met wi-th the approval of many government agencies in many countries, is commercially avail , .
~)455~3 able, and i5 familiar to chemists, the present invention is primarily described in detail in relation to homopolymeric polyglycolic acid.
Polyglycolic acid containing up to 15~ of other un- -its, such as lac-tic acid units, is considered within the term 'polyglycolic acid'l as used herein unless specified as homopolymeric. Other materials such as poly(N~acetyl-D--glucosamine) and polymers of 4-methyl,1,4-dioxane-2,5-dione may be used.
The present invention is particularly useful with tissue absorbable polymers which are insoluble in common organic solvents.
The foam should conform to the surface of the tissue.
Conformation comprises an assessment of the suppleness, re-siliency, and foam's ability to mimic the topography of the wound in such a fashion that there is a minimum gap between the tissue and the foam which minimizes air gaps and pools of liquid. If pools of liquid build up, whether of serum or blood, such pools may become sites for the growth of unde-sirable microorganisms, particularly for external dressings.
If the foam conforms adequately to the surface of the wound, the body's own defense mechanisms are effective up to the zone of contact with the foam, and bacterial contamination is minimized.
- .
DRAWINGS
FIGURE 1 shows a scanning electron microscope photo-micrograph at 50 diameters magnification of the surface of a frozen and dried sample produced in accordance with Example .
FIGURE 2 is a portion of the same structure at 300 diameters magnification.
25 ,013 ~. .
~ 855~
~IGURE 3 is a photomicrograph similar to FIGURE 1 ::
at 50 diameters magnifieation of the reverse side of the same structure.
FIGURE 4 is the same surface as FIGURE 3, but a-t 5 300 diameters magnification.
FIGURE 5 is a razor cut cross section of the same sample as FIGURE 1 at 50 diameters magnification.
FIGURE 6 is the same razor cut cross section as FIGURE 5 at 300 diameters magnification. ;~
A scale on each photomicrograph shows relative sizes.
As exemplified by the drawing, the polyglycolic acid ,-~forms ribbons and shows a fibrillar structure with the ribbons, sheets and fibers intereonnected with many of -the ribbons having eonsiderable greater width than thickness. ~he thiek-ness in general is within the range of~from about 1 to 5mierons. The drled strueture is spongy in eharacter but re-silient so as to be conformable to a wound surfaee and is no-t friable and brittle as are most frozen-dried solids in whieh the solids are dried from an agueous system.
Example 1 Polygl~eolie Aeid in Hexafluoroisoprop~l Aleohol 10.3 Grams of low erystallinity homopolymerie poly-glyeolie aeid was dissolved in 150 milllliters of hexafluoro-isopropyl aleohol by stirring at 36 to 37C. until solution resulted ~about 3 hours). The resulting solution was freed from dust and inadvertent traee eontaminants by fil-tration through a sintered glass filter~ and transferred to a flat bottom dish. An additional 100 milliliters of hexafluoroiso-propyl aleohol was used to dilute the solution to about L~o eoneentration (wt./vol.). The dish was surrounded by a solid earbon dioxide-aeetone mixture until the solution was solidly frozen. The dish in its frozen eondition was plaeed in a resin kettle whieh was sealed and eonneeted to a h-Lgh ~ . .
25,013 ~ ~ 4 5 ~ ~ ~
vacuum system. Vacuum was maintained using a solid carbon dioxide acetone cooled trap to protect -the vacuum pump for 16 hours during which time the kettle was allowed to warm up with the hexafluoroisopropyl alcohol being maintained in its ;
solid state by evaporative cooling, and with no meltbacks.
After the thus formed foam had only a few percen-t residual hexafluoroisopropyl alcohol therein, the foam cake was re-moved, cut into 1/8 inch thick slices and further subjected to vacuum and heat at about 55C. until substantiall~ all of .,. , the hexafluoroisopropyl alcohol was removed.
m e solvent free foam was placed in strippable packages, sterilized with 12~o ethylene oxide in dichlorodi-fluoromethane and thus kept dry and sterile untll -time of use.
~ s a hemostatic sponge, the foam conEorms well to a wound and arrests the flow of blood immediately. ~he initial arresting of bleeding is largely mechanical. Blood then coagu- -lates in the sponge, which both arrests the further flow of blood, and tends to hold the sponge in position. The slices can be cut or broken into a size and shape adapted to cover a particular wound. ~he foam is usable in a wound whlch is to be closed, such as, for example, on the surface of the liver wi-th the foam being closed into -the abdominal cavity, or it may be used on the surface of the body as protection, and allowed to remain until the wound is healed. The foam may be used as an absorbent to absorb blood and other fluids at the site of a wound to dry the wound for subsequent suturing or closing as reguired by a particular surgical procedure.
In test animals on sacrifice, the foam is found to be essentially absorbed within 90 days.
,: .....
,', '' ., . : . . . . .. .. :
5~8 'Example 2 Polyglycollc Acid in Hexafluoroacetone Sesquihydrate 1.9 Grams of homopolymeric polyglycolic acid was dissolved in 45 ml. of hexafluoroacetone sesquihydrate by heating the mixture of 50C with stirrinq for three hours, yielding a solution having a concentration of approximately 4~2%(wt./vol.). The solution was filtered through a sintered glass filter and transferred to a flat dish and the clear ' amber solution was qet in a solid carbon dioxide-acetone mix-ture for about an hour until frozen completely solid.
The dish was then placed in a vacuum chamber and the hexafluoroacetone sesquihydrate was sublimed off at a reduced pressure of about 1 torr. A~ter about 24 hours, the spongelike foam obtained was removed, sliced into 1/8 inch thick slices, and again placed in a closed chamber evacuated '~
at 1 torr. with heating to about 80C for seyeral days. The product was then essentially free from solvent. The slices were sealed in strippable packages, sterilized with ethylene oxide and kept dry until time for use, using techniques rou-tinely employed for polyglycolic acid sutures.
The sponge was an effective absorbent for blood and served as an effeckive hemostat on wound surfaces.
In accordance with conventional usage in the poly-mer field, the polymers herein described are named from the monomer or monomers from which the polymers can be considered as formed. For instance, the key polymer, polyglycolic acid, is so~named whether made from glycolic acid or glycolide, ~ ' even though the units in the chain could properly be describ-ed as glyco1yl linkage~. Particularly, when considered with the prior art, and commercial usage in the field, such nomen-clature is regarded as historically the most signiEicant and the least ambiguous.
_ g .` !.. ~.1 ','. ` :
.. . .. , , , . . .. ,` ,, '' ,' ~ ' `: '
Surgical sponges find many uses in which an ab~
sorbent sponge is desirable to soak up blood, serum, or other body fluids, which sponges are removed and discarded. Cotton gauze sponges are used in many instances. When used inter-nally, there is a problem of part of the sponge coming off -and leaving threads or larger portions of the sponge in the wound. Concern over leaving a sponge in a patient complicates operating room practice and involves extremely rigorous count-ing procedures to insure that no sponge is accidentally left in a closed wound.
In many surgical procedures reguiring a hemostat to control bleeding sutures and tieoffs can be used. In some in-stances it is highly desirable that additional methods of controlling bleeding be made available. More or less success-ful efforts have been made to secure conformable hemostats which can be used to control bleeding and then left in the wound. The problem is well recognized and more acceptable - devices are in constant demand. ~
DESCRIP~ION 0~ TH~ PRIOR AR~ ~ -The use of polyglycolic acid is disclosed in a series of patents and applications to Schmitt, et al: -. .
U. S. Patent 3,297,033, Schmitt and Polistina, January 10, 1967, SURGICAL SUTURES, discloses polyhydroxy--acetic ester absorbable sutures. ~he material is also called polyglycolic acid, and is disclosed as permitting small quan- ~ -tities of comonomers to be present, such as dl-lactic acid, its optically active forms, homologs and analogs. A small - ~-quantity is recognized by the art as up to 15%, as shown by : , ~- 30 U. S. Patent 2,668,162, ~owe, ~ebruary 2, 1954, PREPARATION
0~ HIGH MO~ECU~AR WEIGH~ PO~YHYDROXY-ACETIC ES~ER. -~ ~
. ~:
. . ~, . . .
25,013 55~8 U. S. Patent 3,463,158, Schmitt and Polistina, August 26, 1969, PO~YGLYCOLIC ACID PROS~HETIC DEVICES, dis-closes surgical uses of polyglycolic acid, and incorporates definitions of some terms.
U. S. Patent 3,620,218, Schmitt and Polistina, November 16, 1971, CY~INDRICAL PROS~HE~IC DEVICES OF PO~Y-G~YCOLIC ACID, lists many uses of polygl~colic acid.
U. S. Patent 3,736,646, Schmit-t and Epstein, June 5, 1973, METHOD OF A~rlACHING SURGICA~ NEEDLES TO MUL~IFILAMEN~ -PO~YGLYCO~IC ACID ABSORBABIE SUTURES, discloses surgical elements of a copolymer containing from 15 to 8~ mol percent glycolic acid and 85 to 15 mol percent lactic acid.
U. S. Patent 3,739,773, Schmitt and Polistina, June 19, 1973, PO~YG~YCOLI~ ~CID PROS~HEr~IC DEVIC~S, claims particularly bone pins, plates, nails and screws of polygly-colic acid.
U. S. Application Serial No. 365,656, Schmitt and Polistina, May 31, 1973, SURGICA~ DRESSI~GS 0~ ABSORBABLE
POLYMERS, discloses additional subject matter on surgical dressings of polyglycolic acid. ;-~
U. S. Patent 3,739,773, supra, lis-ts a number of U~ S. patents on methods for preparing polyglycolic acid and starting materials therefor.
In U. S. Ratent 3,620,218, supra, in Column 2 are Z5 listed a number of medical uses of polyglycolic acids, in~
cluding in Column 2; line 52, knit-ted or woven fibrillar products, including velours, and mentioning specifically in -line 53, burn dressings; line 57, felt or sponge for liver hemostasis; line 63, foam as absorbable prosthesis; and in -lines 74 and 75~ burn dressings (in combination with other polymeric films).
U. S. Patent 3,737,440, Schmitt and Bailey, June 5 . . . - -3L~45S48 1973, POLYGLYCOLIC ACID IN SOLUTIONS, discloses solutions of polyglycolic acid in hexafluoroisopropyl alcohol and hexa- ~`
fluoroacetone sesquihydrate, as well as wet and dry spinning of filaments and casting of films using t:hese solutions.
U.S Patent 3,783,093, Gallacher, January 1, 1974, FIBROUS POLYETHYLENE MATERIALS, discloses a fibrillated ma-terial, mentioning poly(glycolic acid) among others~ in which one resin is mixed and fibrillated with another, and one resin leached out to give the product, a web of oriented, intercon-nected directional fiber-like strands, membranes, ribbons, branched ribbons and fibrils. These can be used as bandages and for other medical purposes. Example 15 shows 25 parts of poly(glycolic acid) and 75 parts of poly (methyl methacrylate) leached with acetone.
US Patent 2,899,362, Sieger, Valentine, and Weiden-heimer, Augu~t 11, 1959, HEMOSTATIC SPONGES AND METHOD OF PRE-PARING SAME, discloses a whipped starch-gelatin mixture which is aerated and dried to form a sponge which may be used for hemostatic purposes.
US Patent 3,653,383, Wise, April 4, 1972, ALGIN
SPONGE AND PROCESS THEREFOR, discloses algin sponges made by freeze-drying aqueous alginate dispersions or gels which can be used for burn dressings, and other surgical purposes. The product after use is water-disintegrative.
Commercially, an oxidized regenerated cellulose is available, as a gelatin foam distributed in sheet form. Both oE these are absorbable in tissues. Under some conclitions, the gelatin foam causes bile cysts. It is desirably wetted with saline at the time of use.
~ .
`
`` 3L~)~55~
The use of gauzes, felts, and knitted fabr;cs as a wound dressing is quite conventional. The use of collagenous products as a sponge or pad has been disclosed. The requirements for surgical hemostats are varied and more satisfactory hemostats than presently available are constantly in demand.
The present invention provides a method of making a hemostat comprising dissolving a ~issue-absorbable polymer seLected from polyglycolic acid, poly~N-acetyl-D-glucosamine), and poly(4-methyl, 1,4-dioxane 2,5-dione) in hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering to remove any insoluble contaminants, freezing the solution and subliming off the solvent, whereby an absorbable sponge fibrillar structure is formed ~ -from ribbons having a thickness within the range of from 1 to 5 microns which is essentially non-directional and is readily conformable to tissue surfaces.
The present invention also provides a hemostatic surgical sponge of a tissue absorbable polymer selected from polyglycolic acid, polyXN-acetyl-D-glucosamine), and poly(~-methyl,1,4-dioxana-2,5-dione) in the form of a fibrillar sheet having interconnected ribbons having a thickness within the range of from 1 to 5 microns oriented anisotropically having a network of connecting elements, and which is sufficiently flexible to be readily con-formable to a wound surface.
Such sponges may be used in procedures in which the foam sponge is to be left in the wound and absorbed by body tissues and also sees great acceptance in sponges which are used to absorb blooa, serum or other liquids with the sponge being Temoved and discarded. Because there is the ever present risk of part of the sponge falling off and being left in the wound or through inadvertence being closed in the wound, it is desirable that tissue absorbable sponges be used for general surgical use, wherever tissue may grow into the sponge.
A sponge should have high absorptive capacity, should absorb :;~ ,.' .'""~:, ~, ..
~455~
fluids, particularly blood, rapidly, should be strong enough to be readily handled in surgical procedures, and conformable enough that it fits into whatever topography and space that is available, and be soft enough so that it does not injure sensitive tissues.
The absorbability of the present sponges by the body reduces the risks from the inadvertent enclosure of portions of a hemostatic sponge in living tissue--because such portions are absorbed and removed by the tissue itself.
- 4a -: -25,013 ~ S ~8 Although freeze drying is a well-known technique~
it i5 usually drying of water from frozen compositions in which water is to be removed by sublimation; and the product is usually rather brittle and friable so that it is not readily conformable, and is easily broken.
Here the solvent, which is removed by sublimation, is hexafluoroisopropyl alcohol or hexafluoroace-tone sesqui-hydrate or a mixture of the two. The residual foam is softer and more conformable than products usually secured ``
from aqueous systems. I-t is, of course, not possible to use an aqueous system with the tissue absorbable polymer of this invention. ~he polymers are not water soluble.
Because ~he solvent is volatile, and is sublimed to remove the major portion, and the resulting cake is dried to remove the small remaining portion, the absorbable sponge `
struc-ture is more readily freed from other components than in a leach technique using a mixture of polymers in which ;~
one polymer is leached ou-t, thus requiring elimination of not only the leached polymer, but also the leaching solvent.
Because the term "freeze-drying" sometimes implies an agueous system, the term "sublimation-drying" is used in many places herei~ to accen-tuate tha-t it is an organic sol- ~`
vent system which is being subllmed so tha-t it could be ;
called solven-t-sublimation for sponge manufacture. Products prepared in an aqueous system are generally friable. Using -hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate as a solvent for polyglycolic acid, and other tissue absorbable compositions~ yields a product which is readily flexible and tissue conformable.
3 Because homopolymeric polyglycolic acid is currently being used in sutures, has met wi-th the approval of many government agencies in many countries, is commercially avail , .
~)455~3 able, and i5 familiar to chemists, the present invention is primarily described in detail in relation to homopolymeric polyglycolic acid.
Polyglycolic acid containing up to 15~ of other un- -its, such as lac-tic acid units, is considered within the term 'polyglycolic acid'l as used herein unless specified as homopolymeric. Other materials such as poly(N~acetyl-D--glucosamine) and polymers of 4-methyl,1,4-dioxane-2,5-dione may be used.
The present invention is particularly useful with tissue absorbable polymers which are insoluble in common organic solvents.
The foam should conform to the surface of the tissue.
Conformation comprises an assessment of the suppleness, re-siliency, and foam's ability to mimic the topography of the wound in such a fashion that there is a minimum gap between the tissue and the foam which minimizes air gaps and pools of liquid. If pools of liquid build up, whether of serum or blood, such pools may become sites for the growth of unde-sirable microorganisms, particularly for external dressings.
If the foam conforms adequately to the surface of the wound, the body's own defense mechanisms are effective up to the zone of contact with the foam, and bacterial contamination is minimized.
- .
DRAWINGS
FIGURE 1 shows a scanning electron microscope photo-micrograph at 50 diameters magnification of the surface of a frozen and dried sample produced in accordance with Example .
FIGURE 2 is a portion of the same structure at 300 diameters magnification.
25 ,013 ~. .
~ 855~
~IGURE 3 is a photomicrograph similar to FIGURE 1 ::
at 50 diameters magnifieation of the reverse side of the same structure.
FIGURE 4 is the same surface as FIGURE 3, but a-t 5 300 diameters magnification.
FIGURE 5 is a razor cut cross section of the same sample as FIGURE 1 at 50 diameters magnification.
FIGURE 6 is the same razor cut cross section as FIGURE 5 at 300 diameters magnification. ;~
A scale on each photomicrograph shows relative sizes.
As exemplified by the drawing, the polyglycolic acid ,-~forms ribbons and shows a fibrillar structure with the ribbons, sheets and fibers intereonnected with many of -the ribbons having eonsiderable greater width than thickness. ~he thiek-ness in general is within the range of~from about 1 to 5mierons. The drled strueture is spongy in eharacter but re-silient so as to be conformable to a wound surfaee and is no-t friable and brittle as are most frozen-dried solids in whieh the solids are dried from an agueous system.
Example 1 Polygl~eolie Aeid in Hexafluoroisoprop~l Aleohol 10.3 Grams of low erystallinity homopolymerie poly-glyeolie aeid was dissolved in 150 milllliters of hexafluoro-isopropyl aleohol by stirring at 36 to 37C. until solution resulted ~about 3 hours). The resulting solution was freed from dust and inadvertent traee eontaminants by fil-tration through a sintered glass filter~ and transferred to a flat bottom dish. An additional 100 milliliters of hexafluoroiso-propyl aleohol was used to dilute the solution to about L~o eoneentration (wt./vol.). The dish was surrounded by a solid earbon dioxide-aeetone mixture until the solution was solidly frozen. The dish in its frozen eondition was plaeed in a resin kettle whieh was sealed and eonneeted to a h-Lgh ~ . .
25,013 ~ ~ 4 5 ~ ~ ~
vacuum system. Vacuum was maintained using a solid carbon dioxide acetone cooled trap to protect -the vacuum pump for 16 hours during which time the kettle was allowed to warm up with the hexafluoroisopropyl alcohol being maintained in its ;
solid state by evaporative cooling, and with no meltbacks.
After the thus formed foam had only a few percen-t residual hexafluoroisopropyl alcohol therein, the foam cake was re-moved, cut into 1/8 inch thick slices and further subjected to vacuum and heat at about 55C. until substantiall~ all of .,. , the hexafluoroisopropyl alcohol was removed.
m e solvent free foam was placed in strippable packages, sterilized with 12~o ethylene oxide in dichlorodi-fluoromethane and thus kept dry and sterile untll -time of use.
~ s a hemostatic sponge, the foam conEorms well to a wound and arrests the flow of blood immediately. ~he initial arresting of bleeding is largely mechanical. Blood then coagu- -lates in the sponge, which both arrests the further flow of blood, and tends to hold the sponge in position. The slices can be cut or broken into a size and shape adapted to cover a particular wound. ~he foam is usable in a wound whlch is to be closed, such as, for example, on the surface of the liver wi-th the foam being closed into -the abdominal cavity, or it may be used on the surface of the body as protection, and allowed to remain until the wound is healed. The foam may be used as an absorbent to absorb blood and other fluids at the site of a wound to dry the wound for subsequent suturing or closing as reguired by a particular surgical procedure.
In test animals on sacrifice, the foam is found to be essentially absorbed within 90 days.
,: .....
,', '' ., . : . . . . .. .. :
5~8 'Example 2 Polyglycollc Acid in Hexafluoroacetone Sesquihydrate 1.9 Grams of homopolymeric polyglycolic acid was dissolved in 45 ml. of hexafluoroacetone sesquihydrate by heating the mixture of 50C with stirrinq for three hours, yielding a solution having a concentration of approximately 4~2%(wt./vol.). The solution was filtered through a sintered glass filter and transferred to a flat dish and the clear ' amber solution was qet in a solid carbon dioxide-acetone mix-ture for about an hour until frozen completely solid.
The dish was then placed in a vacuum chamber and the hexafluoroacetone sesquihydrate was sublimed off at a reduced pressure of about 1 torr. A~ter about 24 hours, the spongelike foam obtained was removed, sliced into 1/8 inch thick slices, and again placed in a closed chamber evacuated '~
at 1 torr. with heating to about 80C for seyeral days. The product was then essentially free from solvent. The slices were sealed in strippable packages, sterilized with ethylene oxide and kept dry until time for use, using techniques rou-tinely employed for polyglycolic acid sutures.
The sponge was an effective absorbent for blood and served as an effeckive hemostat on wound surfaces.
In accordance with conventional usage in the poly-mer field, the polymers herein described are named from the monomer or monomers from which the polymers can be considered as formed. For instance, the key polymer, polyglycolic acid, is so~named whether made from glycolic acid or glycolide, ~ ' even though the units in the chain could properly be describ-ed as glyco1yl linkage~. Particularly, when considered with the prior art, and commercial usage in the field, such nomen-clature is regarded as historically the most signiEicant and the least ambiguous.
_ g .` !.. ~.1 ','. ` :
.. . .. , , , . . .. ,` ,, '' ,' ~ ' `: '
Claims (6)
1. A method of making a hemostat comprising dis-solving a tissue-absorbable polymer selected from polygly--colic acid, poly(N-acetyl-D-glucosamine), and poly(4-methyl, 1,4-dioxane-2,5-dione) in hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering to remove any in-soluble contaminants, freezing the solution and subliming off the solvent, whereby an absorbable sponge fibrillar struc-ture is formed from ribbons having a thickness within the range of from 1 to 5 microns which is essentially non-direc--tional and is readily conformable to tissue surfaces.
2. The method of Claim 1 in which the tissue ab-sorbable polymer comprises glycolic acid, having such a high glycolic acid content that it is insoluble in common organic solvents.
3. The method of Claim 2 in which the tissue ab-sorbable polymer is homopolymeric polyglycolic acid.
4. A hemostatic surgical sponge of a tissue ab-sorbable polymer selected from polyglycolic acid, poly(N--acetyl-D-glucosamine), and poly(4-methyl,1,4-dioxane-2,5--dione) in the form of a fibrillar sheet having interconnec-ted ribbons having a thickness within the range of from 1 to 5 microns oriented anisotropically having a network of con-necting elements, and which is sufficiently flexible to be readily conformable to a wound surface.
5. The sponge of Claim 4 in which the tissue ab-sorbable polymer comprises glycolic acid, having such a high glycolic acid content that it is insoluble in common organic solvent.
6. The sponge of Claim 4 in which the tissue ab-sorbable polymer is homopolymeric polyglycolic acid.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US454353A US3902497A (en) | 1974-03-25 | 1974-03-25 | Body absorbable sponge and method of making |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1045548A true CA1045548A (en) | 1979-01-02 |
Family
ID=23804270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA219,627A Expired CA1045548A (en) | 1974-03-25 | 1975-02-07 | Tissue absorbable polymer sponge |
Country Status (9)
Country | Link |
---|---|
US (1) | US3902497A (en) |
JP (1) | JPS51116079A (en) |
AR (1) | AR205109A1 (en) |
BR (1) | BR7531268A (en) |
CA (1) | CA1045548A (en) |
DE (1) | DE2513159A1 (en) |
FR (1) | FR2265412B1 (en) |
GB (1) | GB1490425A (en) |
IT (1) | IT1050278B (en) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3937223A (en) * | 1974-04-19 | 1976-02-10 | American Cyanamid Company | Compacted surgical hemostatic felt |
US4186448A (en) * | 1976-04-16 | 1980-02-05 | Brekke John H | Device and method for treating and healing a newly created bone void |
US4181983A (en) * | 1977-08-29 | 1980-01-08 | Kulkarni R K | Assimilable hydrophilic prosthesis |
ATE142236T1 (en) * | 1984-03-06 | 1996-09-15 | United States Surgical Corp | A METHOD FOR PREPARING TWO-PHASE COMPOSITIONS FOR ABSORBABLE SURGICAL EQUIPMENT |
JPS61149160A (en) * | 1984-12-22 | 1986-07-07 | 株式会社 日本メデイカル・サプライ | Biodegradable absorbable sponge and its production |
US5904717A (en) * | 1986-01-28 | 1999-05-18 | Thm Biomedical, Inc. | Method and device for reconstruction of articular cartilage |
US4744365A (en) * | 1986-07-17 | 1988-05-17 | United States Surgical Corporation | Two-phase compositions for absorbable surgical devices |
US4840626A (en) * | 1986-09-29 | 1989-06-20 | Johnson & Johnson Patient Care, Inc. | Heparin-containing adhesion prevention barrier and process |
US5567612A (en) * | 1986-11-20 | 1996-10-22 | Massachusetts Institute Of Technology | Genitourinary cell-matrix structure for implantation into a human and a method of making |
US6309635B1 (en) | 1986-11-20 | 2001-10-30 | Children's Medical Center Corp. | Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo |
FI81498C (en) * | 1987-01-13 | 1990-11-12 | Biocon Oy | SURGICAL MATERIAL OCH INSTRUMENT. |
US5354290A (en) * | 1989-05-31 | 1994-10-11 | Kimberly-Clark Corporation | Porous structure of an absorbent polymer |
CA2017570C (en) * | 1989-05-31 | 2000-12-19 | James R. Gross | Porous structure of an absorbent polymer |
DE4001833A1 (en) * | 1990-01-23 | 1991-08-01 | Juergen Dr Fischer | Bleeding-prevention instrument in bone cavity - has small-volume implant expanded by fluid after insertion |
DE4034921C2 (en) * | 1990-11-01 | 1994-09-08 | Kulicke Werner Michael Prof Dr | Use of a moisture-storing, cotton-like plastic in upholstery and mattresses |
CA2060635A1 (en) * | 1991-02-12 | 1992-08-13 | Keith D'alessio | Bioabsorbable medical implants |
US5320624A (en) * | 1991-02-12 | 1994-06-14 | United States Surgical Corporation | Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made therefrom |
US6228954B1 (en) | 1991-02-12 | 2001-05-08 | United States Surgical Corporation | Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorabable surgical devices made therefrom |
WO1993007913A1 (en) * | 1991-10-24 | 1993-04-29 | Children's Medical Center Corporation | Neomorphogenesis of urological structures in vivo from cell culture |
US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
US5403347A (en) * | 1993-05-27 | 1995-04-04 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
US5522841A (en) * | 1993-05-27 | 1996-06-04 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
AU8095694A (en) * | 1993-10-28 | 1995-05-22 | Thm Biomedical, Inc. | Improved process and device for treating and healing a bone void |
US5502092A (en) * | 1994-02-18 | 1996-03-26 | Minnesota Mining And Manufacturing Company | Biocompatible porous matrix of bioabsorbable material |
US5431679A (en) * | 1994-03-10 | 1995-07-11 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
US5981825A (en) * | 1994-05-13 | 1999-11-09 | Thm Biomedical, Inc. | Device and methods for in vivo culturing of diverse tissue cells |
US5855608A (en) | 1994-05-13 | 1999-01-05 | Thm Biomedical, Inc. | Device and methods for in vivo culturing of diverse tissue cells |
US5578662A (en) | 1994-07-22 | 1996-11-26 | United States Surgical Corporation | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
US6339130B1 (en) * | 1994-07-22 | 2002-01-15 | United States Surgical Corporation | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
US6206908B1 (en) | 1994-09-16 | 2001-03-27 | United States Surgical Corporation | Absorbable polymer and surgical articles fabricated therefrom |
US5618313A (en) * | 1994-10-11 | 1997-04-08 | United States Surgical Corporation | Absorbable polymer and surgical articles fabricated therefrom |
US5716404A (en) * | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
US6123727A (en) * | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
US5855610A (en) * | 1995-05-19 | 1999-01-05 | Children's Medical Center Corporation | Engineering of strong, pliable tissues |
US5741685A (en) * | 1995-06-07 | 1998-04-21 | Children's Medical Center Corporation | Parenchymal cells packaged in immunoprotective tissue for implantation |
US6129761A (en) * | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
CA2195384C (en) | 1996-01-19 | 2007-06-05 | Kung Liu Cheng | Absorbable polymer blends and surgical articles fabricated therefrom |
US6191236B1 (en) | 1996-10-11 | 2001-02-20 | United States Surgical Corporation | Bioabsorbable suture and method of its manufacture |
US6007565A (en) * | 1997-09-05 | 1999-12-28 | United States Surgical | Absorbable block copolymers and surgical articles fabricated therefrom |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
US5948829A (en) * | 1997-11-25 | 1999-09-07 | Kimberly-Clark Worldwide, Inc. | Process for preparing an absorbent foam |
US6277927B1 (en) | 1997-11-26 | 2001-08-21 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
US5935127A (en) * | 1997-12-17 | 1999-08-10 | Biomet, Inc. | Apparatus and method for treatment of a fracture in a long bone |
JPH11203837A (en) | 1998-01-16 | 1999-07-30 | Sony Corp | Editing system and method therefor |
US6296645B1 (en) | 1999-04-09 | 2001-10-02 | Depuy Orthopaedics, Inc. | Intramedullary nail with non-metal spacers |
US6783529B2 (en) | 1999-04-09 | 2004-08-31 | Depuy Orthopaedics, Inc. | Non-metal inserts for bone support assembly |
US6808527B2 (en) | 2000-04-10 | 2004-10-26 | Depuy Orthopaedics, Inc. | Intramedullary nail with snap-in window insert |
US20040241211A9 (en) * | 2000-11-06 | 2004-12-02 | Fischell Robert E. | Devices and methods for reducing scar tissue formation |
US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
US7897832B2 (en) * | 2001-06-14 | 2011-03-01 | Hemcon Medical Technologies, Inc. | Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan |
US20050147656A1 (en) * | 2001-06-14 | 2005-07-07 | Hemcon, Inc. | Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
US20060004314A1 (en) * | 2001-06-14 | 2006-01-05 | Hemcon, Inc. | Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan |
US7371403B2 (en) | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
WO2002102276A2 (en) | 2001-06-14 | 2002-12-27 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
US8269058B2 (en) * | 2002-06-14 | 2012-09-18 | Hemcon Medical Technologies, Inc. | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
US6863924B2 (en) * | 2002-12-23 | 2005-03-08 | Kimberly-Clark Worldwide, Inc. | Method of making an absorbent composite |
DE602004032514D1 (en) | 2003-01-09 | 2011-06-16 | Polyganics Bv | BIOMEDICAL FOAM |
US20050020899A1 (en) * | 2003-07-25 | 2005-01-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatmetn implants and methods |
US7537788B2 (en) | 2003-07-25 | 2009-05-26 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US7744852B2 (en) | 2003-07-25 | 2010-06-29 | Rubicor Medical, Llc | Methods and systems for marking post biopsy cavity sites |
US7655009B2 (en) | 2003-12-01 | 2010-02-02 | Smith & Nephew, Inc. | Humeral nail |
US20050148963A1 (en) * | 2004-01-05 | 2005-07-07 | Brennan H. G. | Bioabsorbable surgical sponge |
US7410488B2 (en) | 2005-02-18 | 2008-08-12 | Smith & Nephew, Inc. | Hindfoot nail |
US9204957B2 (en) * | 2005-03-17 | 2015-12-08 | Hemcon Medical Technologies, Inc. | Systems and methods for hemorrhage control and or tissue repair |
EP2026850B1 (en) * | 2006-05-23 | 2014-07-09 | Providence Health System-Oregon d/b/a Providence St. Vincent Medical Center | Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ |
KR101548766B1 (en) * | 2008-05-02 | 2015-08-31 | 프로비던스 헬스 앤드 서비시즈, 오레곤 | Wound dressing devices and methods |
EP2340002B1 (en) | 2008-10-06 | 2015-03-25 | Providence Health System - Oregon | Foam medical devices and methods |
CA2745867A1 (en) * | 2008-12-31 | 2010-07-08 | Kci Licensing, Inc. | Systems for providing fluid flow to tissues |
US20180296313A1 (en) | 2015-09-23 | 2018-10-18 | Novus Scientific Ab | Three-dimensional medical implant for regeneration of soft tissue |
US11254061B2 (en) * | 2017-01-06 | 2022-02-22 | Ethicon, Inc. | Scaffolds for implanting absorbable hemostats in field conditions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3297033A (en) * | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
US3666750A (en) * | 1969-12-15 | 1972-05-30 | Johnson & Johnson | Hemostatic material |
US3801675A (en) * | 1970-02-20 | 1974-04-02 | Johnson & Johnson | Polymer blend containing polyacrylic acid,polyvinyl alcohol,and a polyacrylate |
US3772136A (en) * | 1971-04-20 | 1973-11-13 | Gen Mills Inc | Fibrous products from thermoplastic polyamide polymers |
US3705585A (en) * | 1971-07-15 | 1972-12-12 | Dennis W Saffro | Preformed surgical sponge |
US3825007A (en) * | 1972-01-07 | 1974-07-23 | R Rand | Pledgets |
-
1974
- 1974-03-25 US US454353A patent/US3902497A/en not_active Expired - Lifetime
-
1975
- 1975-01-01 AR AR257766A patent/AR205109A1/en active
- 1975-02-07 CA CA219,627A patent/CA1045548A/en not_active Expired
- 1975-02-12 GB GB6053/75A patent/GB1490425A/en not_active Expired
- 1975-02-18 IT IT8230/75A patent/IT1050278B/en active
- 1975-03-04 BR BR1268/75A patent/BR7531268A/en unknown
- 1975-03-25 DE DE19752513159 patent/DE2513159A1/en not_active Withdrawn
- 1975-03-25 JP JP50035036A patent/JPS51116079A/en active Pending
- 1975-03-25 FR FR7509310A patent/FR2265412B1/fr not_active Expired
Also Published As
Publication number | Publication date |
---|---|
US3902497A (en) | 1975-09-02 |
BR7531268A (en) | 1975-12-23 |
JPS51116079A (en) | 1976-10-13 |
IT1050278B (en) | 1981-03-10 |
AR205109A1 (en) | 1976-04-05 |
FR2265412B1 (en) | 1978-10-06 |
FR2265412A1 (en) | 1975-10-24 |
AU7822275A (en) | 1976-08-19 |
GB1490425A (en) | 1977-11-02 |
DE2513159A1 (en) | 1975-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1045548A (en) | Tissue absorbable polymer sponge | |
US3988411A (en) | Spinning and shaping poly-(N-acetyl-D-glucosamine) | |
US4074366A (en) | Poly(N-acetyl-D-glucosamine) products | |
JP5638521B2 (en) | Healing wound dressing that reduces temperature | |
RU2468129C2 (en) | Biopolymeric fibre, composition of forming solution for its obtaining, method of forming solution preparation, linen of biomedical purpose, biological bandage and method of wound treatment | |
AU2003204986B2 (en) | Hemostatic wound dressing and method of making same | |
Qin | The gel swelling properties of alginate fibers and their applications in wound management | |
EP0815879B1 (en) | Bioabsorbable medical devices from oxidized polysaccharides | |
US4524064A (en) | Wound-covering materials | |
EP2156849B1 (en) | A chitosan based fiber material, preparing method and application thereof | |
EP1481694A1 (en) | Biodegradable hemostatic wound dressings | |
MXPA06007345A (en) | Wound d/ressing and method for controlling severe, life-threatening bleeding. | |
JP2007516050A (en) | Wound dressing and method for controlling life-threatening serious bleeding | |
EP0772463B1 (en) | Alginate fibre, process for the preparation thereof and use | |
KR102164819B1 (en) | Apparatus for hemostasis and method for manufacturing the same | |
US20090214667A1 (en) | Medical technical product, method for producing the same and providing the same for surgery | |
WO2007056066A2 (en) | Bioabsorbable hemostatic gauze | |
CA2433980A1 (en) | Wound dressing containing aldehyde-modified regenerated polysaccharide | |
CA2155518A1 (en) | Pharmaceutical compositions comprising a spongy material consisting of ester derivatives of hyarulonic acid combined with other pharmacologically active substances | |
KR100748348B1 (en) | Method of manufacturing hydrogel for wound treatment using irradiation technology | |
CN115475276A (en) | Hemostatic material and wound dressing containing same | |
KR100608192B1 (en) | Method for manufacturing neutralized chitosan sponge for wound coating material and tissue engineering structure and neutralized chitosan sponge produced thereby | |
KR100546793B1 (en) | Foam dressing using chitosan and its manufacturing method | |
JP2008525112A (en) | Antimicrobial barriers, systems and methods formed from hydrophilic polymer structures such as chitosan | |
WO2025004113A1 (en) | A non-adherent absorbent article |